Methadone
Sold as Equity-methadone, Methadone adco, Rutrex, Misyo, Epatadone, Lometasan, Physeptone
6-(Dimethylamino)-4,4-diphenylheptan-3-one
Drag to rotate. Structure from PubChem CID 4095.
Background
Registration
- Applicants
- 6
- Registrations
- 8
- Schedule source
- SAHPRA documentation
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Equity Pharmaceutical (Pty) LtdCertificate held by Equity Pharmaceuticals (Pty) Ltd | Equity-methadone, Epatadone | 2 mg / 1 ml, 10 mg/ml | 430539, 570630 | S6 | PIPIL |
| Adcock Ingram Critical Care (Pty) Ltd | Methadone adco | 10mg | 540839 | S6 | PIPIL |
| Arya Pharma (Pty) LtdCertificate held by Lebasi Pharmaceuticals (Pty) Ltd | Rutrex, Lometasan | 0,4 mg/mL, 10 mg | 550235, 570847 | S6 | PIPIL |
| Umsebe healthcare | Misyo | 10 mg/ml | 550741 | S6 | None |
| Pharmacare limited û woodmead | Physeptone | injection | B0771 | S6 | None |
| Acino Pharma (Pty) LtdCancelled | Physeptone | linctus | G0523 | S6 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Equity-methadone EACH 1,0 ml SOLUTION CONTAINS METHADONE HYDROCHLORIDE 2,0 mg | 2 mg / 1 mlOral solution | 43053943/2.9/0539Approved 21 January 2024 | Registered | S6 | PIPIL |
| Methadone adco 10 MG EACH 1,0 ml SOLUTION CONTAINS METHADONE HYDROCHLORIDE 10,0 mg | 10mgOral solution | 54083954/2.9/0839Approved 4 March 2025 | Registered | S6 | PIPIL |
| Rutrex Each 1,0 ml solution contains: METHADONE HYDROCHLORIDE 10,0 | 10 mgConcentrate for oral solution | 55023555/2.9/0235Approved 14 March 2023 | Registered | S6 | PIPIL |
| Misyo 10 mg/ml EACH 1,0 ml SOLUTION CONTAINS METHADONE HYDROCHLORIDE 10,0 mg | 10 mg/ml | 55074155/2.9.0741 | Registered | S6 | None |
| Epatadone 10 mg/ml Each 1,0 ml solution contains: Methadone Hydrochloride 10,0 mg | 10 mg/ml | 57063057/2.9/0630 | Registered | S6 | None |
| Lometasan 1 mg/ml Each 1,0 ml solution contains: METHADONE HYDROCHLORIDE 1,0 mg | 0,4 mg/mLOral solution | 57084757/2.9/0847Approved 10 June 2025 | Registered | S6 | PIPIL |
| Physeptone injection EACH 1 ml SOLUTION CONTAINS METHADONE HYDROCHLORIDE A 10 mg | Injection | B0771 | Old Medicine | S6 | None |
| Physeptone linctus EACH 5 ml SYRUP CONTAINS METHADONE HYDROCHLORIDE A 2 mg | Linctus | G0523 | Cancelled | S6 | None |
Regulatory status
Where S6 sits on the scale
Prescription-only, no repeats without a new prescription.
Schedule 6 covers the most tightly controlled ordinary prescription medicines. Every dispensing needs its own new prescription; nothing can be repeated on the same script. When prescribed, the quantity must be written out in both figures and words. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S6, read from the product's PI-PIL leaflet.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it.
Consolidated Schedules listings for Methadone hydrochloride
S6: Methadone
Consolidated Schedules 06 July 2026, line 10300
Pharmacological class: Other analgesics. (class 2.9)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Equity-methadone, Equity Pharmaceutical (Pty) Ltd is scheduled S6 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.